Literature DB >> 2438783

Clinical experience with tetracycline pleurodesis of malignant pleural effusions.

S Sherman, K J Grady, J C Seidman.   

Abstract

Because many patients with malignant pleural effusions could survive for months to years beyond its onset, definitive management must be safe and effective. Chemical pleurodesis with tetracycline has gained general acceptance as the therapy of choice, even though no large series confirming this viewpoint has appeared in the literature. We reviewed 108 procedures involving tube thoracostomy and tetracycline pleurodesis, and report a success rate of 94.4% without serious complications. Considering all patients, 49% were symptom-free at three months, and 13% were alive one year later. Several potentially important changes in technique have emerged since the initial description of this procedure. With adherence to meticulous technique, tetracycline pleurodesis provides rapid, effective, and safe palliation of malignant pleural effusions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2438783     DOI: 10.1097/00007611-198706000-00013

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  4 in total

1.  BTS guidelines for the management of malignant pleural effusions.

Authors:  G Antunes; E Neville; J Duffy; N Ali
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

Review 2.  Pleural effusion.

Authors:  A R Medford; A Medford; N Maskell
Journal:  Postgrad Med J       Date:  2005-11       Impact factor: 2.401

3.  Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions.

Authors:  A G Villanueva; A W Gray; D M Shahian; W A Williamson; J F Beamis
Journal:  Thorax       Date:  1994-01       Impact factor: 9.139

4.  Pleurodesis with povidone iodine in patients with malignant pleural effusion in a tertiary center in Nigeria.

Authors:  Benjamin Irene Omoregbee; Stanley Okugbo
Journal:  Pan Afr Med J       Date:  2021-02-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.